Xingyao Y. Bu
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Leucine-rich pentatricopeptide repeat-containing protein silencing transcriptionally regulated by GATA-binding protein 3 has an anti-glioma effect by regulating glycolysis and ferroptosis by mediating N6-methyladenosine modification of protocadherin-7.
Journal: Journal of neuropathology and experimental neurology
Published: February 02, 2026
Identification of hsa-miR-144-3p as a novel immunotherapeutic target for glioblastoma based on disulfidptosis-related analysis.
Journal: Discover oncology
Published: September 25, 2025
Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial.
Journal: Cancer
Published: September 05, 2025
Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis.
Journal: Neuro-oncology advances
Published: September 04, 2025
Clinical characteristics and prognostic analysis of calcified glioblastoma.
Journal: Medicine
Published: July 23, 2025
In Reply: Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.
Journal: Neurosurgery
Published: June 16, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Journal: Frontiers in oncology
Published: February 21, 2025
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.
Journal: Journal of cancer research and clinical oncology
Published: June 18, 2024
Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.
Journal: Neurosurgery
Published: June 09, 2024
New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.
Journal: Frontiers in immunology
Published: May 24, 2024
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
Journal: Cancer immunology, immunotherapy : CII
Published: May 08, 2024
Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.
Journal: Cancer medicine
Published: March 16, 2024
Last Updated: 09/26/2026